Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 1/20 | 0.39 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | REN | P00797 | 1/20 | 0.32 |
| ▸ | PGD | P52209 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7401175 | 1.00 | MMP13 (0.39) | MMP13AAK1GAAMEN1KMT2A | |
| SCHEMBL27908634 | 1.00 | MMP13 (0.39) | MMP13AAK1GAAMEN1KMT2A | |
| SCHEMBL23879143 | 0.88 | MMP13 (0.37) | MMP13AAK1HDAC6HDAC1HDAC2 | |
| SCHEMBL18248121 | 0.87 | MMP13 (0.38) | MMP13AAK1GAAMEN1KMT2A | |
| SCHEMBL21435676 | 0.87 | MMP13 (0.38) | MMP13AAK1GAAMEN1KMT2A | |
| SCHEMBL2581321 | 0.86 | AAK1 (0.38) | MMP13AAK1GAAMEN1KMT2A | |
| SCHEMBL626316 | 0.85 | AAK1 (0.39) | MMP13AAK1GAAMEN1KMT2A | |
| SCHEMBL1162878 | 0.85 | MMP13 (0.39) | MMP13AAK1GAAMEN1KMT2A | |
| SCHEMBL953166 | 0.85 | MMP13 (0.39) | MMP13AAK1GAAMEN1KMT2A | |
| SCHEMBL626315 | 0.85 | AAK1 (0.39) | MMP13AAK1GAAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12018048-B2 | Anthelmintic depsipeptide compounds | Boehringer Ingelheim Animal Health USA Inc. (US) | 2024-06-25 | — | — | US | disclosed |
| EP-3397638-B1 | ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS | BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC (US) | 2023-08-23 | — | — | EP | disclosed |
| US-11382949-B2 | Anthelmintic depsipeptide compounds | Boehringer Ingelheim Animal Health USA Inc. (US) | 2022-07-12 | — | — | US | disclosed |
| US-20220098241-A1 | ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS | Boehringer Ingelheim Animal Health USA Inc. (US) | 2022-03-31 | — | — | US | disclosed |
| US-11230571-B2 | Anthelmintic depsipeptide compounds | Boehringer Ingelheim Animal Health USA Inc. (US) | 2022-01-25 | — | — | US | disclosed |
| EP-3922639-A1 | ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS | Boehringer Ingelheim Animal Health USA Inc. (US) | 2021-12-15 | — | — | EP | disclosed |
| EP-3298027-B1 | ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS | BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC (US) | 2021-04-28 | — | — | EP | disclosed |
| US-20200354408-A1 | ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS | Boehringer Ingelheim Animal Health USA Inc. (US) | 2020-11-12 | — | — | US | disclosed |
| US-10793604-B2 | Anthelmintic depsipeptide compounds | Boehringer Ingelheim Animal Health USA Inc. (US) | 2020-10-06 | — | — | US | disclosed |
| US-20190307838-A1 | ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS | Boehringer Ingelheim Animal Health USA Inc. (US) | 2019-10-10 | — | — | US | disclosed |
| WO-2016187534-A1 | ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS | MERIAL, INC. (US) | 2016-11-24 | — | — | WO | disclosed |
| EP-0593603-B1 | BICYCLIC FIBRINOGEN ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2002-11-20 | — | — | EP | disclosed |
| US-6403578-B1 | ANTICOAGULANTS, CARDIOVASCULAR DISORDERS | SMITHKLINE BEECHAM CORPORATION | 2002-06-11 | — | — | US | disclosed |
| US-6127359-A | Bicyclic fibrinogen antagonists | SMITHKLINE BEECHAM CORPORATION (US) | 2000-10-03 | — | — | US | disclosed |
| US-5939412-A | Bicyclic fibrinogen antagonists | SMITHKLINE BEECHAM CORPORATION (US) | 1999-08-17 | — | — | US | disclosed |
| US-5693636-A | Bicyclic fibrinogen antagonists | SMITHKLINE BEECHAM CORPORATION (US) | 1997-12-02 | — | — | US | disclosed |
| EP-0674623-A1 | BICYCLIC FIBRINOGEN ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1995-10-04 | — | — | EP | disclosed |
| WO-1994014776-A2 | BICYCLIC FIBRINOGEN ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1994-07-07 | — | — | WO | disclosed |
| EP-0593603-A1 | BICYCLIC FIBRINOGEN ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1994-04-27 | — | — | EP | disclosed |
| WO-1993000095-A2 | BICYCLIC FIBRINOGEN ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1993-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12018048-B2 | Anthelmintic depsipeptide compounds | VIP, DNPEP, DPEP1 | MMP13 434/4885AAK1 3150/4885GAA 1692/4885 |
| US-11382949-B2 | Anthelmintic depsipeptide compounds | ENPP2, ROCK2, RRP12 | MMP13 1446/4885AAK1 3576/4885GAA 4780/4885 |
| US-10793604-B2 | Anthelmintic depsipeptide compounds | VIP, PREP, DNPEP | MMP13 504/4885AAK1 3412/4885GAA 2604/4885 |
| US-20220098241-A1 | ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS | VIP, PREP, DNPEP | MMP13 440/4885AAK1 3436/4885GAA 2706/4885 |
| US-20190307838-A1 | ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS | ENPP2, ROCK2, RRP12 | MMP13 1446/4885AAK1 3576/4885GAA 4780/4885 |
| US-20200354408-A1 | ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS | VIP, PREP, DNPEP | MMP13 504/4885AAK1 3412/4885GAA 2604/4885 |
| US-11230571-B2 | Anthelmintic depsipeptide compounds | VIP, PREP, DNPEP | MMP13 440/4885AAK1 3436/4885GAA 2706/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.